Plain-English translation of NCT07225894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers in Kenya tested whether a series of theater plays could help reduce stigma and negative attitudes toward PrEP (pre-exposure prophylaxis), a medication that helps prevent HIV infection in people at high risk. The trial involved young women who used or had used PrEP, as well as community members and audience members who watched the performances. The goal was to see if theater could be an effective way to change how people think and feel about HIV prevention.
Many young women in Kenya face stigma and judgment when considering or using HIV prevention medication, which can prevent them from accessing this important health tool. Researchers wanted to test whether creative interventions like theater could help reduce these harmful attitudes in communities and make it easier for women to protect their health.
Participants were assigned to different groups. Some young women attended all six theater performances in a single week, while others served as a comparison group and did not watch the plays. Community members and audience members who attended the performances were also followed to see how the plays affected their views on HIV prevention. Researchers gathered feedback from participants about whether and how the theater performances influenced their attitudes toward PrEP stigma.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Kenya
Collaborators
National Institutes of Health (NIH), Fogarty International Center of the National Institute of Health
Enrollment target
~144 participants
Started
December 2025
Primary completion
March 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.